Cancer-associated carbohydrates identified by monoclonal antibodies

S Sell1

  • 1Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston 77225.

Human Pathology
|October 1, 1990
PubMed

Insights

Cancer cells exhibit altered carbohydrate structures, acting as biomarkers for diagnosis and prognosis. These oncodevelopmental antigens, identified by monoclonal antibodies, offer insights into cancer progression and metastasis.

Area of Science:

  • Biochemistry
  • Oncology
  • Glycobiology

Background:

  • Cancer cells display unique carbohydrate structures on their surface or secreted.
  • These structures, recognized as epitopes by monoclonal antibodies, arise from altered glycosylation pathways.
  • Aberrant fucosylation, sialylation, and incomplete glycosylation are observed in various cancer types.

Purpose of the Study:

  • To review novel carbohydrate structures associated with cancer.
  • To discuss their potential roles in cancer diagnosis, prognosis, and metastasis.
  • To explore the oncodevelopmental nature of cancer-associated carbohydrates.

Main Methods:

  • Review of scientific literature on cancer-associated carbohydrate antigens.
  • Analysis of monoclonal antibody-defined epitopes on cancer cells.
  • Examination of alterations in glycolipid and glycoprotein glycosylation patterns.

Main Results:

  • Identification of key carbohydrate epitopes, including CA 15.3, CA 19.9, CA 125, and B72.3.
  • Demonstration of aberrant glycosylation in O-linked mucin oligosaccharides and glycolipids.
  • Observation that cancer-associated glycosylation patterns often mirror normal developmental stages.

Conclusions:

  • Cancer-associated carbohydrate structures serve as valuable diagnostic and prognostic biomarkers.
  • These oncodevelopmental antigens may play roles in cell recognition, metastasis, and cancer progression.
  • Further research into the biological significance of cell surface carbohydrates in cancer is warranted.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...